STMicroelectronics Works with Alifax on Rapid, Cost-Efficient Point-of-Care Medical Testing
STMicroelectronics Works with Alifax on Rapid, Cost-Efficient
Point-of-Care Medical Testing
- Alifax, a diagnostic-test producer, has customized biological content and reagents to detect pandemic-related genetic material and other viral (and bacterial) pathogens
- ST Real-Time PCR molecular-diagnostics technology, using disposable chip-based cartridges, can be adapted to detect any genetic material
Geneva, Switzerland, and Padova, Italy, October 29, 2020 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, and Alifax S.r.l, a producer of clinical diagnostic instrumentation, have worked together on a rapid, cost-efficient portable solution that will be available from Alifax, for point-of-care molecular diagnostic detection using highly reliable real-time Polymerase Chain Reactions (PCR) to amplify genetic material (RNA and DNA1) in patient samples.
Leveraging technology developed and licensed from ST, Alifax is manufacturing the Molecular Mouse, a small portable instrument that contains a broad range of ST components, including STM32 MCUs, sensors, amplifiers, and other devices. Connected to a PC, the Molecular Mouse uses medical reagents2 created by Alifax to manage the control and testing of multiple targets or samples on a tiny disposable cartridge, manufactured by ST using its high-volume Micro-Electro-Mechanical Systems (MEMS) semiconductor process technology. Test results are available in less than hour.
“One crucial lesson from the current global pandemic is the importance of rapid, cost-efficient point-of-care testing that allows immediate remote diagnosis, and then, if necessary, patient isolation,” said Alessandro Cremonesi, Chief Innovation Officer, STMicroelectronics. “ST has been investing in its Real-Time PCR platform convinced that innovative semiconductor-based diagnostic solutions can positively impact our lives.“
“Leveraging our high-volume semiconductor-manufacturing technology and long-term leadership in microfluidics, we’ve developed a rapidly customizable, highly flexible cartridge and instrumentation platform that delivers rapid and precise point-of-care diagnostic results, which Alifax has used to respond almost immediately to present pandemic and future diagnostic needs,” added Benedetto Vigna, President Analog MEMS, and Sensors Group, STMicroelectronics.
STMicroelectronics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de